The contribution of the renin-angiotensin-aldosterone system (RAAS) to central nervous system (CNS) disorders is not yet fully understood. RAAS has been shown to be involved in the proliferation of astrocytes, which have a role in neuronal damage contributing to neurodegenerative diseases. However, the direct relationship between RAAS and neuronal damage is still unclear. We therefore examined the effect of angiotensin (Ang) II and aldosterone (Aldo) on damage to spinal ganglion neurons (SGNs) by regulating astrocytes. Ang II stimulation significantly increased DNA damage in SGNs in a time-dependent manner. This increase in DNA damage was further enhanced when SGNs were co-cultured with astrocytes. On the other hand, no significant increase was observed in SGNs co-cultured with astrocytes without Ang II stimulation. Moreover, the addition of conditioned medium from Ang II-treated astrocytes exacerbated SGN DNA damage. An Ang II type 1 receptor blocker, valsartan, inhibited Ang II-stimulated DNA damage but not DNA damage induced by conditioned medium prepared from astrocyte cultures. In contrast, an Aldo antagonist, eplerenone, significantly inhibited DNA damage induced by the culture medium from Ang II-treated astrocytes. Ang II-stimulated Aldo secretion in the conditioned medium from astrocytes. Furthermore, the administration of Aldo alone also enhanced DNA damage in SGNs. Finally, flow cytometric analysis showed that Ang II or Aldo treatment markedly increased the percentage of dead SGNs. In conclusion, Ang II-and Aldo-induced neuronal damage in SGNs through astrocytes regulation. Blocking Ang II and Aldo to target astrocytes might be useful for the treatment of CNS disorders.
INTRODUCTION
Central nervous system (CNS) disorders, including neurodegenerative diseases such as Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis (ALS), are characterized by neuronal dysfunction and degeneration within various regions of the brain and/or the spinal cord. 1 Astrocytes are the most numerous non-neuronal cell type in the CNS, and they perform multiple functions essential to normal neuronal modulation. 2 However, astrocytes have recently been implicated in the dynamic regulation of neuronal degeneration in several specific neurodegenerative diseases. It has been suggested that the astrocyte-induced increase in neuronal C1q expression could damage neuronal integrity and cause the loss of neurons, leading to the pathogenesis of Alzheimer disease. 3 More recent studies revealed that astrocytes expressing a mutated form of the gene for the ubiquitously expressed Cu/Zn superoxide dismutase (SOD) 1 protein induce neuronal death in ALS patients. 4 These findings indicate that astrocytes might participate in neurotoxic mechanisms to induce neuronal damage, leading to CNS dysfunction. There are reports further suggesting that astrocytes might be associated with the induction of oxidative stress to promote DNA damage resulting in neuronal degeneration. 5, 6 However, the more detailed cellular mechanisms involved in the neuron-astrocyte interaction that regulates neuronal damage remain largely unknown.
The renin-angiotensin-aldosterone system (RAAS) is well known to contribute to hypertension and cardiovascular disease, and inhibitors of RAAS are widely used as antihypertensive and cardiovasculature-protective drugs. 7 However, accumulating evidence shows that RAAS that is localized in the CNS also has an important role in CNS disorders. 8, 9 Recently, increased attention has focused on understanding the involvement of RAAS in the pathogenesis of neurodegenerative diseases. Kawajiri et al. 10 observed a reduced Ang II level in the cerebrospinal fluid of patients with ALS. Moreover, in vitro and in vivo studies showed that an inhibitor of RAAS, olmesartan, has a neurotrophic effect on neurons in the spinal cord of the ALS rat, implicating a potential therapeutic use of olmesartan in inhibiting neuronal degeneration for the treatment of neurodegenerative diseases. 11 However, the direct role of RAAS in regulating neuronal damage is not clear.
Angiotensin (Ang) II and aldosterone (Aldo) are two important effectors of RAAS and have a variety of pathophysiological actions via binding to the Ang II type 1 (AT 1 ) receptor and mineralocorticoid receptor (MR), respectively. 12, 13 Along with others, we have demonstrated that Ang II often cross-talks with Aldo to mediate cardiovascular remodeling through an interaction between the AT 1 receptor and MR activation. 14, 15 The AT 1 receptor and MR have been clearly identified in numerous specific regions in the brain and spinal cord. 16, 17 Moreover, it has been suggested the AT 1 receptor and MR are expressed in cultured astrocytes and neurons 18, 19 and mediate Ang II-induced astrocyte proliferation. 18 Numerous studies indicate that Ang II and Aldo are key stimulators of oxidative stress, which can trigger multiple signaling mechanisms in the CNS and in the cardiovascular system. 20, 21 Therefore, we speculate that the interaction of Ang II with Aldo might be related to neuronal damage with possible involvement of astrocyte function through oxidative stress, thereby contributing to the pathogenesis of CNS disorders. To address this hypothesis, we examined the effects of Ang II and Aldo on neuronal damage by evaluating a marker of oxidative DNA damage using cultured spinal ganglion neurons (SGNs). We also employed SGN-astrocyte co-cultures to clarify the involvement of astrocytes in Ang II-and Aldo-induced damage to neurons.
METHODS

Cell culture
This study was performed in accordance with the National Institutes of Health guidelines for the use of C57BL/6J mice (Clea Japan, Osaka, Japan). Neurons were prepared from embryonic day 20 mouse spinal ganglia between the thoracic and sacral level, as described previously, with minor modifications according to the standard culture technique of nerve tissue. 22 After dissection, SGNs were dissociated by incubation with 2.5% trypsin (Invitrogen, Carlsbad, CA, USA) and DNase for 30 min at 37 1C. SGNs were then mechanically triturated into a single-cell suspension with a pipette and syringe in Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Invitrogen), 100 ng ml -1 nerve growth factor (Sigma-Aldrich, St Louis, MO, USA) and antibiotics (PenStrep; Invitrogen). After centrifugation and resuspension in growth medium, the cells were plated in six-well dishes prepared for co-culture with astrocytes and cultured at 37 1C in a humidified atmosphere of 5% CO 2 and 95% air. Three days after plating, cultures were treated with 10 À6 mol l -1 cytosine arabinoside for 2 days, yielding a stable population of neurons without supporting Schwann cells or fibroblasts. The neurons were then maintained in fresh growth medium that was replaced every 2 days for 1 week until use. The purity of cultured SGNs was 495%, as detected by the immunofluorescent staining of microtubuleassociated protein 2 (MAP2).
Astrocytes were obtained from neonatal day 0-2 mice, as described previously, with minor modifications according to the standard culture technique. 23 Briefly, newborn mice were decapitated and the cerebral cortices were removed. After removal of the meninges, the cerebral cortices were digested with 0.4 mg ml -1 dispase (Invitrogen) for 15 min. The digested tissue was dissociated with a pipette and syringe in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics and passed through a strainer (Biosciences Discovery Labware, Two Oak Park, Bedford, MA, USA) to remove organized debris. The cells were cultured in 6-well or 24-well dishes at 37 1C in a humidified atmosphere of 5% CO 2 and 95% air. Twenty-four hours after the initial plating, the medium was changed to preserve adhering astrocytes and to remove neurons and oligodendrocytes. The cultures were maintained in growth medium that was replaced every 2 days for 1 week until the experiments. The purity of cultured astrocytes was 495%, as detected by the immunofluorescent staining of glial fibrillary acidic protein (GFAP).
For SGN-astrocyte co-cultures, astrocytes were seeded in six-well dishes with a Falcon Cell Culture Insert (FCCI) of 1-mm pore size (Becton Dickinson Labware, Franklin Lakes, NJ, USA). After stimulation with or without Ang II for 24 h, astrocytes with a FCCI were placed on the top of the six-well dishes cultured with SGNs, and the co-cultures were maintained in SGN culture medium for the indicated times.
Quantification of 8-hydroxy-2¢-deoxyguanosine (8-OHdG)
The immunoreactivity of 8-OHdG in the DNA of SGN was detected by an enzyme-linked immunosorbent assay. 24 Briefly, genomic DNA was extracted using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA), and the 8-OHdG level in 20 mg sample DNA was measured using an 8-OHdG Check ELISA Kit (Japan Institute for the Control of Aging, Shizuoka, Japan). The ratio of ng 8-OHdG mg -1 DNA was calculated.
Measurement of Aldo concentration
The Aldo concentration was measured as previously described. 14 Subconfluent and quiescent cells that were cultured in 24-well dishes in 1 ml Dulbecco's modified Eagle's medium growth medium per well were incubated with or without Ang II in phenol red-free Dulbecco's modified Eagle's medium for the indicated times. At the end of the incubation period, a 200-ml aliquot of the supernatant was removed to measure the Aldo concentration using an Aldo ELISA Kit (Alpha Diagnostic International, San Antonio, TX, USA). The cells were isolated with trypsin to determine the cell count.
Cell death detection assay SGN death was determined by flow cytometric analysis using a BD Cell Viability Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. Briefly, cells were harvested and resuspended in staining buffer consisting of phosphate-buffered saline, 0.01% Tween-20 and 1 mmol l -1 EDTA. Five minutes after staining with thiazole orange solution and propidium iodide at room temperature, the cells were analyzed using a flow cytometer (FACSCalibur, BD, Franklin Lakes, NJ, USA) in combination with software (CellQuest, BD).
Materials
Valsartan was donated by Novartis Pharma AG (Basel, Switzerland), and Eplerenone was donated from Pfizer (New York, NY, USA). All other reagents not mentioned above were purchased from Sigma-Aldrich.
Statistical analysis
All values in the text and figures are expressed as mean±s.e.m. Data were evaluated by analysis of variance followed by post hoc analysis for multiple comparisons. Differences with Po0.05 were considered significant.
RESULTS
The presence of astrocytes enhances Ang II-induced DNA damage in SGNs
We examined the effect of Ang II on DNA damage in SGNs via the possible cross-talk with astrocytes by quantitating 8-OHdG levels in an SGN-astrocytes co-culture system. Cell cultures were divided into five groups: (1) SGN only, (2) SGN stimulated with Ang II directly, (3) SGN with FCCI with Ang II addition for 24 h, (4) SGN with FCCI cultured with astrocytes and (5) SGN with FCCI cultured with Ang II-treated astrocytes for 24 h. These culture systems were each maintained for 1, 3 or 5 days, and 8-OHdG levels in the SGNs were then measured. Ang II stimulation (100 nM) significantly increased 8-OHdG levels in SGNs in a time-dependent manner by direct (group 2) and indirect (group 3) stimulation methods. These 8-OHdG levels in SGNs were further enhanced when the cells were co-cultured with Ang II-stimulated astrocytes (group 5). However, co-culture with astrocytes alone did not increase the 8-OHdG levels in SGNs (group 4) (Figure 1 ). These results suggest that Ang II might promote SGN DNA damage via cross-talk with astrocytes.
Eplerenone, but not valsartan, inhibits DNA damage in SGNs cultured in Ang II-treated astrocyte-conditioned medium Next, we examined the effect of an AT 1 receptor blocker, valsartan, on Ang II-induced SGN DNA damage in relation to astrocytes. Cultures were designed to subject SGNs to different treatments for 3 days as follows: without any stimulation; stimulated with Ang II in the presence or absence of valsartan; stimulated with culture medium of Ang II with or without valsartan-treated astrocytes; stimulated with Ang II and culture medium from Ang II-treated astrocytes (conditioned medium); stimulated with valsartan or eplerenone and conditioned medium. SGNs were subjected to different treatments for 3 days by changing the old medium every 24 h with freshly prepared medium containing Ang II and/or valsartan and freshly prepared astrocytes culture medium. Astrocytes were stimulated with Ang II with or without valsartan for 24 h. Ang II or conditioned medium increased 8-OHdG levels in SGNs, and 8-OHdG levels in SGNs stimulated with Ang II and conditioned medium were higher than those in SGNs stimulated with Ang II or conditioned medium alone. The administration of valsartan (10 mM) significantly inhibited the Ang II-induced 8-OHdG levels in SGNs. However, valsartan did not alter the 8-OHdG levels in SGNs stimulated with the conditioned medium ( Figure 2) . In contrast, a mineralocorticoid receptor antagonist, eplerenone (10 mM), strongly blocked 8-OHdG levels in SGNs stimulated with the conditioned medium regardless of the presence of valsartan (Figure 3) . These results show that Aldo secreted from Ang II-stimulated astrocytes might have an important role in inducing DNA damage in SGNs.
Aldo secreted by Ang II-stimulated astrocytes promotes DNA damage in SGNs To examine whether Aldo is secreted by Ang II-simulated astrocytes, astrocytes were stimulated with or without Ang II by changing the old medium every 24 h with freshly prepared medium with or without Ang II, after which the Aldo concentration in the Ang II-treated astrocyte-conditioned medium was measured. With Ang II stimulation, Aldo concentration in the astrocyte-conditioned medium increased in a time-dependent manner. However, Aldo secretion was not observed in the astrocyte-conditioned medium without Ang II stimulation (Figure 4a ). We also examined the Aldo concentration in the medium from Ang II-stimulated SGNs. The stimulation methods for SGNs were identical to those for astrocytes. The Aldo concentration in the SGN-conditioned medium increased in a time-dependent manner after Ang II addition (Figure 4b ). SGNs were then stimulated with Aldo (1 nM) alone for 1, 3 and 5 days, and DNA damage was analyzed to determine the possible involvement of Aldo in inducing DNA damage in SGNs. We observed that Aldo stimulation significantly enhanced the 8-OHdG levels in SGNs in a time-dependent manner starting at 3 days of treatment (Figure 4b) .
Ang II or Aldo stimulation induces cell death in SGNs
To detect whether Ang II-or Aldo-induced DNA damage in SGNs leads to cell death, we treated SGNs with Ang II or Aldo for 3 days and performed flow cytometric analysis. Figure 5a shows the dot-plot graph of SGN cell viability; dead cells are localized at the top of the plot. We also quantified the mean percentage of dead SGNs, as shown in Figure 5b . Ang II or Aldo stimulation markedly increased the percentage of dead cells in SGNs to 53.3 or 38.5% of the total cells, respectively (Figure 5b ).
DISCUSSION
The cellular and molecular mechanisms involved in neuronal degeneration that contribute to neurodegenerative diseases are multi-factor- ial and complex. There is evidence implicating oxidative stress as a central mechanism by which neuronal damage occurs. 25 There is also new evidence indicating that astrocytes expressing a mutated form of SOD1 may contribute to neuronal degeneration. 4 The mutated SOD1 has been suggested to induce the high production of reactive oxygen species and subsequent DNA damage in neurons. 5 Therefore, many proposed mechanisms of neuronal degeneration suggest that oxidative stress, together with astrocytes, has an essential role in the pathogenesis of neurodegenerative diseases. However, the link between astrocytes and oxidative stress in causing neuronal damage remains to be elucidated. In this study, we demonstrated that Ang II and Aldo promote neuronal damage and death in SGNs through oxidative stress via the involvement of astrocytes. Increasing evidence has revealed the important role of local RAAS in CNS disorders. 8, 9 Inhibitors of RAAS, which are widely used as antihypertensive drugs, may have potential beneficial and therapeutic effects on CNS disorders. We and others have shown that treatment with AT 1 receptor blockers can reduce the ischemic area in the brain and improve cognitive function in various animal models. 26, 27 We have also reported that an MR blocker, eplerenone, attenuates stroke size in mice subjected to ischemic brain damage. 28 Moreover, recent evidence has suggested that AT 1 receptor blockers may reduce the incidence of neurodegenerative diseases. Iwasaki et al. 11 demonstrated that an AT 1 receptor blocker, olmesartan, could reduce neuronal death in the spinal cord of the ALS rat in vivo and in vitro. Wang et al. 29 also reported that another AT 1 receptor blocker, valsartan, could protect against brain b-amyloid-related memory deficit in the Tg 2576 mouse Alzheimer disease model. These findings implicate the AT 1 receptor and MR activation as critical mediators in the pathogenesis of CNS disorders, such as neurodegenerative diseases because of neuronal degeneration. Therefore, to further understand the mechanisms involved in neuronal degeneration, the contributory functions of Ang II and Aldo in neuronal degeneration via the AT 1 receptor and MR activation have to be elucidated. We demonstrated in this study that Ang II stimulation promotes SGN damage and death starting at 3 days of treatment, as determined by the quantification of the levels of 8-OHdG, a marker of oxidative DNA damage. An AT 1 receptor blocker, valsartan, significantly inhibited this Ang II-induced SGN damage. Thus, Ang II might have a role in inducing the SGN damage and death that contributes to the pathogenesis of CNS disorders.
Neuron-astrocyte interaction is involved in the physiological functions of neurons. 30 However, the contribution of astrocytes to neuronal degeneration has only recently been shown. 3, 4 Therefore, we introduced an SGN and astrocyte co-culture model to verify the hypothesis that astrocytes are involved in SGN damage induced by Ang II stimulation. We demonstrated that Ang II-mediated SGN damage increased in the presence of astrocytes when SGNs were co-cultured with Ang II-stimulated astrocytes. However, co-culture with astrocytes without Ang II stimulation did not induce SGN damage. Thus, it is possible that astrocytes might be involved in Ang II-induced SGN damage. Ang II is well known as a critical mediator of oxidative stress, the increased level of which contributes to the CNS effects of Ang II. 20 Therefore, we hypothesized that oxidative stress might be tightly linked with Ang II and astrocytes to promote SGN DNA damage under pathophysiological conditions. Our findings also support the importance of neuron-astrocyte interaction in the progression of neuronal degeneration. However, examination of astrocyte reactivity following SGN damage, such as the proliferation of astrocytes, would contribute to further understanding astrocytes as one of the targets for neuroprotection.
The neuronal toxicity of astrocytes expressing SOD1 appears to be partly due to a soluble factor, because the conditioned medium from astrocytes expressing SOD1 is toxic to neurons. 4 Nerve growth factor and pro-apoptotic mediators have been proposed as the toxic factors. 31 We examined which toxic factors secreted from astrocytes under Ang II stimulation could cause SGN damage. Recent studies have suggested a reciprocal interaction between Ang II and Aldo in mediating hypertension and cardiovascular disease. Aldo secreted by Ang II stimulation in vascular smooth muscle cells contributes to Ang II-mediated proliferation and senescence. 14,32 Therefore, we studied whether Aldo was also synthesized and secreted by Ang II-stimulated astrocytes and participated in the progression of SGN damage by culturing SGNs in astrocyte-conditioned medium. Consistent with the above observations, the addition of the culture medium from Ang IItreated astrocytes to SGNs for 3 days stimulated SGN damage and enhanced Ang II-induced damage. Valsartan inhibited the damageinducing effect of Ang II in the conditioned medium from astrocytes. Therefore, it is possible that AT 1 receptor signaling could contribute to the formation of toxic factors in astrocytes, thereby resulting in SGN damage in response to Ang II. To examine the possibility that Aldo could act through MR to induce SGN damage, we added valsartan and the MR antagonist eplerenone to SGNs when they were stimulated with the culture medium from Ang II-treated astrocytes. Interestingly, eplerenone strongly inhibited SGN damage induced by the culture medium from Ang II-treated astrocytes, whereas valsartan did not alter DNA damage. Indeed, we also observed that the Aldo concentration was increased in the conditioned medium from Ang IIstimulated astrocytes and SGNs, and that Aldo stimulation also enhanced SGN damage and death starting at 3 days of treatment. Therefore, Aldo, as one of the toxic factors secreted from Ang IIstimulated astrocytes, might further result in the formation of toxic factors in SGNs and contribute to Ang II-mediated SGN damage and death via MR activation. Our findings are consistent with the previous observations that Ang II via AT 1 receptor stimulation could induce Aldo release in astrocytes to participate in various pathophysiologic processes, such as hypoxia-associated neurodegeneration. 33 As Aldo also has a direct role in oxidative stress, 21 it seems that oxidative stress may also be related to the neuron-damaging effect of Aldo. More detailed examination of the toxic factors that directly cause SGN damage and the signaling pathways involved in Ang II-and Aldoinduced SGN damage with the involvement of astrocytes could contribute to further elucidation of the pathogenesis of CNS disorders.
Recent studies, including ones by our group, have demonstrated that AT 1 receptor or Aldo blockers have beneficial and possibly therapeutic effects on CNS disorders. We reported that the AT 1 receptor blocker telmisartan prevented ischemic brain damage in diabetic mice, and that telmisartan also has a preventive effect on cognitive impairment in an Alzheimer mouse model, partly as a result of activation of peroxisome proliferator-activated receptor-g. 34, 35 These findings suggest that AT 1 receptor blockers could exert protective effects on the CNS not only directly through an AT 1 receptor or MR blockade, but also via peroxisome proliferator-activated receptor-g activation. These issues should also be clarified in future in vitro studies.
Collectively, the present work shows that Ang II promotes neuronal damage and death in SGNs. In addition, Aldo that is secreted from astrocytes in response to Ang II contributes to Ang II-mediated neuronal damage. Our study identifies potential roles of Ang II and Aldo in inducing neuronal damage through oxidative stress with the involvement of astrocytes. Our findings may provide a novel cellular mechanism of neuronal damage and contribute new insight into the possibility that inhibiting Ang II and Aldo with antihypertensive drugs that target the functional integrity of astrocytes could constitute a superior strategy for the treatment of CNS disorders such as neurodegenerative diseases.
